Background: Thrombotic microangiopathy (TMA) is a potentially life-threatening complication associated with carfilzomib, a proteasome inhibitor approved for treating multiple myeloma. TMA typically presents within the initial months of treatment; however, delayed onset is rare and poses significant diagnostic challenges.

Thrombotic microangiopathy involves tiny clots forming within the microvasculature. This leads to erythrocyte fragmentation (which is termed MAHA: microangiopathic hemolytic anemia). Occlusion of the microvasculature also leads to tissue damage.

The time to onset of G-TMA was defined as: TMA onset date − gemcitabine administration start date + 1. We also studied time to onset by sex, age group, cancer type, TMA classification, and clinical outcomes.

Jan 22, 2015 · Many patients with syndromes of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome, have been reported to have a drug-induced etiology, and many different drugs have been suspected as a cause of TMA.

Aug 14, 2014 · The thrombotic microangiopathy (TMA) syndromes are extraordinarily diverse. They may be hereditary or acquired. They occur in children and adults. The onset can be sudden or gradual.

Sep 23, 2021 · Thrombotic microangiopathy (TMA) is characterized by microvascular endothelial injury and thrombosis, presenting both clinically and histopathologically in two main forms; acute and chronic TMA.

Dec 20, 2024 · Background: Thrombotic microangiopathy (TMA) is a potentially life-threatening complication associated with carfilzomib, a proteasome inhibitor approved for treating multiple myeloma. TMA typically presents within the initial months of treatment; however, delayed onset is rare and poses significant diagnostic challenges.

Apr 19, 2021 · Transplant-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic stem cell transplant (HSCT) with high morbidity and mortality.

Nov 7, 2024 · Proteasome inhibitors (PIs) are crucial in treating multiple myeloma but carry a risk of thrombotic microangiopathy (TMA), especially with carfilzomib use. This systematic review includes 44...

Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic haemolytic anaemia and end organ damage. TMAs have varying underlying pathophysiology and can therefore present with an array of clinical presentations.